archive-com.com » COM » N » NEXTECHINVEST.COM

Total: 35

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Investors | Nextechinvest
    vital drugs will reach the market while at the same time offering attractive returns to investors Nextech III Oncology LPCI Nextech Invest s third fund commenced operations in April 2010 This Swiss limited partnership is fully regulated and operates under the supervision of the Swiss Financial Market Supervisory Authority FINMA For inquiries please contact Alfred Scheidegger Log in Important Legal Notice Nextech III Oncology Kommanditgesellschaft für kollektive Kapitalanlagen the LPCI was authorised as a limited partnership for collective investments Kommanditgesellschaft für kollektive Kapitalanlagen pursuant to Art 13 of the Collective Investment Schemes Act CISA and the limited partnership agreement was approved pursuant to Art 15 CISA by decision of the Swiss Financial Market Supervisory Authority FINMA dated 31 March 2010 Subscription for limited partnership interests in the LPCI is limited to Qualified Investors as defined in Art 10 3 and 4 CISA and Art 6 of the implementing ordinance to the CISA and is further subject to the terms and conditions set out in the limited partnership agreement 21 04 2016 TRACON announces clinical data presentations 17 04 2016 Jounce Therapeutics presents data highlighting Sitemap Sitemap Home About Nextech Invest Oncology Expertise Investment Strategy Selection Process Investment Criteria Team Portfolio

    Original URL path: http://www.nextechinvest.com/en/investors.html (2016-04-26)
    Open archived version from archive


  • News | Nextechinvest
    Meeting 2016 17 03 2016 Kura Oncology reports fourth quarter and full year 2015 operational and financial results 15 03 2016 Blueprint Medicines announces a USD 1B collaboration with Roche to accelerate and expand its development of novel medicines in the field of cancer immunotherapy 11 03 2016 Blueprint Medicines reports fourth quarter and full year 2015 financial results 11 03 2016 Kura Oncology to report fourth quarter and full year 2015 financial results 04 02 2016 Blueprint Medicines appoints Lonnel Coats to Board of Directors 27 01 2016 Tracon Pharmaceuticals announces initiation of TRC102 Phase 2 clinical trial in Glioblastoma 25 01 2016 Tracon Pharmaceuticals announces FDA Orphan Drug Designation for TRC105 in Soft Tissue Sarcoma 21 01 2016 Jounce Therapeutics appoints Perry Karsen to its Board of Directors 11 01 2016 ImaginAb appoints Benjamin Chen Ph D as CEO Joseph Limber as Chairman and forms Medical Advisory Board 06 01 2016 TetraLogic Pharmaceuticals announces data on lead clinical programs 05 01 2016 Blueprint Medicines strengthens executive leadership team 04 01 2016 Sunesis Pharmaceuticals announces European Medicines Agency validates marketing authorization application for Vosaroxin in AML Events 03 06 07 06 2016 ASCO Annual Meeting Chicago USA Past Events 16 04 20 04 2016 AACR Annual Meeting New Orleans USA 04 04 05 04 2016 Cancer Advance Boston Boston USA 21 03 23 03 2016 Immunotherapy of Cancer Conference Munich Germany 15 03 16 03 2016 Annual European Life Science CEO Forum Zürich Switzerland 16 02 17 02 2016 Family Office Forum Dubai UAE 11 01 15 01 2016 J P Morgan 34th Annual Healthcare Conference San Francisco USA Newsletter Keep me updated about investment opportunities in the area of oncology and life sciences Register Latest Newsletters February 2016 November 2015 September 2015 Sitemap Sitemap Home About Nextech Invest

    Original URL path: http://www.nextechinvest.com/en/news.html (2016-04-26)
    Open archived version from archive

  • Careers | Nextechinvest
    Openings Internship in Investor Relations and Communication 100 Internship as Biotech Investment Analyst 100 Sitemap Sitemap Home About Nextech Invest Oncology Expertise Investment Strategy Selection Process Investment Criteria Team Portfolio Investors News Contact Nextech Invest Ltd Turnerstrasse 26 8006 Zurich Switzerland P 41 0 44 366 66 11 F 41 0 44 366 66 10 Newsletter Registration Please fill in the subscription form completely If you wish to modify your

    Original URL path: http://www.nextechinvest.com/en/careers.html (2016-04-26)
    Open archived version from archive

  • Contact | Nextechinvest
    com Download Situation Plan Sitemap Sitemap Home About Nextech Invest Oncology Expertise Investment Strategy Selection Process Investment Criteria Team Portfolio Investors News Contact Nextech Invest Ltd Turnerstrasse 26 8006 Zurich Switzerland P 41 0 44 366 66 11 F 41 0 44 366 66 10 Newsletter Registration Please fill in the subscription form completely If you wish to modify your personal data or to change cancel your newsletter subscription this

    Original URL path: http://www.nextechinvest.com/en/contact.html (2016-04-26)
    Open archived version from archive

  • Team | A Scheidegger | Nextechinvest
    PhD in microbiology from the University of Basel Switzerland and has completed a post doctorate research fellowship in enzymology at the University of Kyoto Japan and an executive training programme at Harvard Business School USA Mr Scheidegger is responsible for the following Nextech Invest portfolio companies TRACON TetraLogic Palyon Molecular MD Portfolio companies Mr Scheidegger has been involved with previously Ganymed Agensys Sitemap Sitemap Home About Nextech Invest Oncology Expertise

    Original URL path: http://www.nextechinvest.com/en/team/a-scheidegger.html (2016-04-26)
    Open archived version from archive

  • Team | T Schroeder | Nextechinvest
    his MSc thesis at the University of Sydney Thilo Schroeder was president of SiROP a web based technology which connects leading universities in Europe and world wide Mr Schroeder is responsible for the following Nextech Invest portfolio companies TRACON Peloton Kura Oncology ImaginAB Blueprint Sitemap Sitemap Home About Nextech Invest Oncology Expertise Investment Strategy Selection Process Investment Criteria Team Portfolio Investors News Contact Nextech Invest Ltd Turnerstrasse 26 8006 Zurich

    Original URL path: http://www.nextechinvest.com/en/team/t-schroeder.html (2016-04-26)
    Open archived version from archive

  • Team | K Kakalacheva | Nextechinvest
    in diverse scientific fields in institutions including Jenner Institute for Vaccine Design Oxford UK Wellcome Trust Centre for Human Genetics Oxford UK and the Swiss Federal Institute of Technology ETH Zurich Switzerland Sitemap Sitemap Home About Nextech Invest Oncology Expertise Investment Strategy Selection Process Investment Criteria Team Portfolio Investors News Contact Nextech Invest Ltd Turnerstrasse 26 8006 Zurich Switzerland P 41 0 44 366 66 11 F 41 0 44

    Original URL path: http://www.nextechinvest.com/en/team/k-kakalacheva.html (2016-04-26)
    Open archived version from archive

  • Team | M Weibel | Nextechinvest
    with UBS graduated at the University of Applied Sciences in Economics and Business Administration and is a Swiss certified expert for accounting and controlling He has a postgraduate degree in leadership and management from the IWB Berufsakademie KV Luzern Sitemap Sitemap Home About Nextech Invest Oncology Expertise Investment Strategy Selection Process Investment Criteria Team Portfolio Investors News Contact Nextech Invest Ltd Turnerstrasse 26 8006 Zurich Switzerland P 41 0 44

    Original URL path: http://www.nextechinvest.com/en/team/m-weibel.html (2016-04-26)
    Open archived version from archive



  •